GUTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Fractyl Health Inc (GUTS) is not a good buy for a beginner, long-term investor at this moment. The stock is in a bearish technical trend, has weak financials, lacks positive news catalysts, and has seen recent downgrades in analyst ratings. While the RSI indicates the stock is oversold, the lack of strong proprietary trading signals and poor financial performance make it unsuitable for a long-term investment strategy.
The stock is in a bearish trend with MACD below 0 and negatively contracting, RSI at 14.181 indicating oversold conditions, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 0.46, with key support at 0.387 and resistance at 0.532.
RSI indicates oversold conditions, which may suggest a potential rebound in the short term. However, this is not sufficient for a long-term buy decision.
Recent downgrades in analyst ratings and price targets.
Weak financial performance with revenue dropping to 0 and gross margin at
Lack of recent positive news or event-driven catalysts.
Bearish technical indicators and market sentiment.
In Q3 2025, the company reported a 100% YoY drop in revenue to 0 and a gross margin of 0. Net income improved to -$45.6M (up 96.79% YoY), and EPS increased to -0.71 (up 47.92% YoY). Despite these improvements, the financials remain weak overall.
Recent analyst ratings have been negative. BofA lowered the price target to $2 from $5, citing imperfect data from the Revita procedure trials. Morgan Stanley downgraded the stock to Equal Weight from Overweight and reduced the price target to $2 from $8, highlighting concerns about weight regain in the Revita trials. Previous optimism from Canaccord in late 2025 has been overshadowed by recent downgrades.
